Publications 2024

Blom KB, Kro GB, Midtvedt K, Jenssen TG, Reisæter AV, Rollag H, Hartmann A, Sagedal S, Sjaastad I, Tylden G, Njølstad G, Nilsen E, Birkeland JA, Åsberg A (2024)
Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation
Front Immunol, 15, 1414830
DOI 10.3389/fimmu.2024.1414830, PubMed 39007131

Publications 2023

Blom KB, Birkeland GK, Midtvedt K, Jenssen TG, Reisæter AV, Rollag H, Hartmann A, Sagedal S, Sjaastad I, Tylden G, Njølstad G, Nilsen E, Christensen A, Åsberg A, Birkeland JA (2023)
Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management
Transplantation, 107 (8), 1846-1853
DOI 10.1097/TP.0000000000004615, PubMed 37211633

Publications 2017

Osnes JB, Skomedal T, Meyerdierks O, Sagedal S, Langberg H, Draganov B (2017)
[Not Available]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.17.0743, PubMed 29043751

Sagedal S, Sandvik L, Klingenberg O, Sandset PM (2017)
β-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane
Scand J Clin Lab Invest, 77 (8), 679-684
DOI 10.1080/00365513.2017.1397288, PubMed 29117741

Publications 2016

Smedbråten J, Mjøen G, Hartmann A, Åsberg A, Rollag H, Mollnes TE, Sandvik L, Fagerland MW, Thiel S, Sagedal S (2016)
Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients
BMC Nephrol, 17 (1), 148
DOI 10.1186/s12882-016-0373-9, PubMed 27760523

Smedbråten J, Sagedal S, Åsberg A, Hartmann A, Rollag H, Mjøen G, Fagerland MW, Hansen SW, Mollnes TE, Thiel S (2016)
Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation
Am J Transplant, 17 (1), 265-271
DOI 10.1111/ajt.13933, PubMed 27341702

Publications 2015

Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
Clin Ther, 37 (7), 1594-9
DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997

Smedbråten YV, Sagedal S, Mjøen G, Hartmann A, Fagerland MW, Rollag H, Mollnes TE, Thiel S (2015)
High ficolin-3 level at the time of transplantation is an independent risk factor for graft loss in kidney transplant recipients
Transplantation, 99 (4), 791-6
DOI 10.1097/TP.0000000000000422, PubMed 25222012

Publications 2013

Smedbråten YV, Sagedal S, Leivestad T, Mjøen G, Osnes K, Rollag H, Reisaeter AV, Foss A, Os I, Hartmann A (2013)
The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival
Clin Transplant, 28 (1), 120-6
DOI 10.1111/ctr.12288, PubMed 24351078

Publications 2012

Smerud KT, Dolgos S, Olsen IC, Åsberg A, Sagedal S, Reisæter AV, Midtvedt K, Pfeffer P, Ueland T, Godang K, Bollerslev J, Hartmann A (2012)
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
Am J Transplant, 12 (12), 3316-25
DOI 10.1111/j.1600-6143.2012.04233.x, PubMed 22946930

Publications 2011

Sagedal S, Witczak BJ, Osnes K, Hartmann A, Os I, Eikvar L, Klingenberg O, Brosstad F (2011)
A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F×8)
Blood Purif, 32 (3), 151-5
DOI 10.1159/000325227, PubMed 21659742

Publications 2009

Manner I, Sagedal S, Røger M, Os I (2009)
Renal amyloidosis in intravenous heroin addicts with nephrotic syndrome and renal failure
Clin Nephrol, 72 (3), 224-8
DOI 10.5414/cnp72224, PubMed 19761730

Publications 2008

Sagedal S, Thiel S, Hansen TK, Mollnes TE, Rollag H, Hartmann A (2008)
Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation
Nephrol Dial Transplant, 23 (12), 4054-60
DOI 10.1093/ndt/gfn355, PubMed 18577532

Publications 2007

Sagedal S, Rollag H, Hartmann A (2007)
Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk
Clin Transplant, 21 (3), 309-13
DOI 10.1111/j.1399-0012.2006.00639.x, PubMed 17488378

Publications 2006

Hartmann A, Sagedal S, Hjelmesaeth J (2006)
The natural course of cytomegalovirus infection and disease in renal transplant recipients
Transplantation, 82 (2 Suppl), S15-7
DOI 10.1097/01.tp.0000230460.42558.b0, PubMed 16858268

Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T (2006)
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
Kidney Int, 69 (3), 588-95
DOI 10.1038/sj.ki.5000116, PubMed 16395250

Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, Hansen TK, Thiel S, Sagedal S, Røislien J, Hartmann A (2006)
Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients
J Am Soc Nephrol, 17 (6), 1746-54
DOI 10.1681/ASN.2005121368, PubMed 16687626

Publications 2005

Degré M, Sagedal S, Rollag H (2005)
Viral infections in immunocompromised patients. A review
Acta Microbiol Immunol Hung, 52 (3-4), 351-62
DOI 10.1556/AMicr.52.2005.3-4.7, PubMed 16400875

Hjelmesaeth J, Müller F, Jenssen T, Rollag H, Sagedal S, Hartmann A (2005)
Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage
Nephrol Dial Transplant, 20 (11), 2311-5
DOI 10.1093/ndt/gfi033, PubMed 16046502

Sagedal S, Hartmann A, Osnes K, Bjørnsen S, Torremocha J, Fauchald P, Kofstad J, Brosstad F (2005)
Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin
Nephrol Dial Transplant, 21 (2), 444-9
DOI 10.1093/ndt/gfi203, PubMed 16234293

Sagedal S, Hartmann A, Rollag H (2005)
The impact of early cytomegalovirus infection and disease in renal transplant recipients
Clin Microbiol Infect, 11 (7), 518-30
DOI 10.1111/j.1469-0691.2005.01190.x, PubMed 15966969

Publications 2004

Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, Nordal KP, Jenssen T (2004)
Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation
Diabetologia, 47 (9), 1550-6
DOI 10.1007/s00125-004-1499-z, PubMed 15338129

Sagedal S (2004)
Prevention of activation of coagulation during haemodialysis and the use of warfarin
Nephrol Dial Transplant, 19 (3), 749; author reply 749-50
DOI 10.1093/ndt/gfg524, PubMed 14767045

Sagedal S (2004)
Cytomegalovirus infection and disease in renal transplantrecipients
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 204, 1 b. (flere pag.)
BIBSYS 041800621, ISBN 82-8072-167-3

Sagedal S, Hartmann A (2004)
Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies
Eur J Med Res, 9 (3), 125-30
PubMed 15096322

Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degré M, Fauchald P, Rollag H (2004)
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival
Kidney Int, 66 (1), 329-37
DOI 10.1111/j.1523-1755.2004.00735.x, PubMed 15200441

Publications 2003

Moen EM, Sagedal S, Bjøro K, Degré M, Opstad PK, Grinde B (2003)
Effect of immune modulation on TT virus (TTV) and TTV-like-mini-virus (TLMV) viremia
J Med Virol, 70 (1), 177-82
DOI 10.1002/jmv.10356, PubMed 12629661

Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, Degré M, Fauchald P, Rollag H (2003)
Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study
Nephrol Dial Transplant, 18 (9), 1899-908
DOI 10.1093/ndt/gfg302, PubMed 12937241

Publications 2002

Rollag H, Sagedal S, Kristiansen KI, Kvale D, Holter E, Degré M, Nordal KP (2002)
Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients
Clin Microbiol Infect, 8 (7), 431-4
DOI 10.1046/j.1469-0691.2002.00449.x, PubMed 12199854

Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H (2002)
The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients
Am J Transplant, 2 (9), 850-6
DOI 10.1034/j.1600-6143.2002.20907.x, PubMed 12392291

Publications 2001

Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F (2001)
Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
Nephrol Dial Transplant, 16 (5), 987-93
DOI 10.1093/ndt/16.5.987, PubMed 11328905

Publications 2000

Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, Osnes K, Leivestad T, Fauchald P, Rollag H (2000)
A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients
Transplantation, 70 (8), 1166-74
DOI 10.1097/00007890-200010270-00007, PubMed 11063335

Publications 1999

Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Fauchald P, Brosstad F (1999)
A single dose of dalteparin effectively prevents clotting during haemodialysis
Nephrol Dial Transplant, 14 (8), 1943-7
DOI 10.1093/ndt/14.8.1943, PubMed 10462275

Publications 1998

Rollag H, Sagedal S, Holter E, Degré M, Ariansen S, Nordal KP (1998)
Diagnosis of cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes
Eur J Clin Microbiol Infect Dis, 17 (2), 124-7
DOI 10.1007/BF01682170, PubMed 9629980

Sagedal S, Asberg A, Hartmann A, Bergan S, Berg KJ (1998)
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients
Clin Transplant, 12 (6), 553-6
PubMed 9850449